Not all identified active compounds have the same chances to progress into a clinical candidate. While several issues can be addressed via computational drug-like filters at the very early stages, other parameters like the capability of a hit compound to be chemically modified may not be immediately straightforward. We analyze the obtained hits from all points of view (IP, drug-likeness, chemical amenability, economical cots, etc) and prioritize them accordingly. 

We quickly select in-stock compound analogs of the obtained active compounds for enabling comprehensive  SARs and Hit Priorization process.